On 15 June 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 58/2022 of 15 June 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the legitimacy of authorising the reimbursement of foodstuffs for particular nutritional uses with regard to MSUD Anamix Infant, MSUD Anamix Junior, MSUD Anamix Junior LQ, MSUD Gel, MSUD Cooler, MSUD Express, MSUD Lophlex LQ for the following indications: maple syrup disease, beta-ketothiolase deficiency, 3‑hydroxyisobutyryl-CoA hydrolase deficiency.
Publication in Public Information Bulletin (BIP)